EQ-5D and the condition specifi c Dermatitis-Life-Quality-Index (DLQI)), direct and indirect costs, from the societal perspective. RESULTS: A preliminary sample of 305 patients (mean age + SD = 41.4 + 14.9, 38.2% male) were enrolled. Two hundred fi fty fi ve patients (83.6%) had CHE and of these the 27.8% were severe. Overall, 20.0% of the enrolled patients were chronic, severe and refractory to therapy. DLQI mean + SD sum score was 10.38 + 5.98. With EQ-5D 92.7% of patients reported moderate or severe pain/discomfort, 70.9% problems with usual activities, 58.2% anxiety/depression and 40% problems with self-care. VAS mean + SD = 61.96 + 21.48. On average hospitalization cost c87.90/patient-month, travels due to CHE cost c69.54/patient-month, specialist visit costs c52.81/patient-month, other products (gloves, gauze bandage, vacuum cleaner, cosmetics) costs c35.70/patient-month, diagnostic exam costs c20.77/patient-month, non pharmacological therapy (emollients, galenic products, soap, UV-ray) cost c15.65/patient-month and pharmacological therapy cost c9.22/patient-month. Patients lost a mean + SD 4.35 + 8.68 workdays/ patient-month for reasons attributable to their condition. CONCLUSIONS: most of the patients in the Italian centers of dermatology have CHE and a fi fth are severe and refractory to therapy. Patients with severe CHE and refractoriness to therapy have poor HRQoL and high costs. a correct diagnosis and treatment is necessary to efficiently manage this condition.
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University Clinics of Hamburg, Hamburg, Germany; 2 University Heidelberg, Heidelberg, Germany; 3 Basilea Pharmaceutica, Basel, Switzerland OBJECTIVES: It is assumed broadly that the costs caused by chronic hand eczema (CHE) are signifi cant. However, there is a lack of cost-of-illness studies on CHE. The objective of this study is, therefore, to determine the direct and indirect costs of chronic hand eczema under routine conditions overall and in different treatment stages in Germany. METHODS: The survey was conducted in 24 outpatient practices and clinics across Germany. Patients with CHE refractory to potent topical treatments and insured by statutory health insurances were eligible. Patient characteristics and resource use were directly gathered from patients and physicians. Costs were evaluated from the societal perspective. Four treatment stages were defi ned: only topical treatments (stage I), additionally photo therapy (II), systemic therapy (III) and inpatient treatment (IV). Bivariate associations between costs and treatment stage were assessed. RESULTS: A total of 223 CHE patients enrolled in the study. The yearly direct and indirect costs per patient are c1742 (SE: c139) and c386 (c83), respectively. a total of 63.2% of patients were treated only with topical treatments; additionally 15.7% with photo therapy, 11.7% with systemic treatments. a total 9.4% of all patients were admitted to hospitals. The total costs increase with treatment stage I-IV (P < 0.001): c1044 (c85), c2307 (c145), c2697 (c461) and c8407 (c991), respectively. Accordingly, costs also correlated with clinical severity. CONCLUSIONS: CHE patients refractory to topical steroids incur marked costs to the society. The costs are increasing disproportionately with escalating treatment stages, especially in patients admitted to hospitals. Hence, new and innovative treatments may help to reduce the societal costs of CHE.
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COST OF GLAUCOMA IN THE UNITED KINGDOM ACCORDING TO THE UK GPRD
Salmon J 1 , Lafuma A 2 , Robert J 2 , Berdeaux G 3 1 Oxford Eye Hospital, Oxford, UK; 2 CEMKA-EVAL, Bourg la Reine, France; 3 Alcon France, Rueil-Malmaison, France OBJECTIVES: The objective of this analysis was to estimate the total budget dedicated to glaucoma care according to the UKGPRD and to identify factors associated with high costs. METHODS: Data were extracted on patients treated on the National Health Service with a diagnosis of ocular hypertension or glaucoma, or treated with topical intraocular lowering treatment, surgery or laser for glaucoma. The budget was estimated from resources consumed in 2008 and included glaucoma drugs, laser, surgery, hospitalization, specialist and general practitioner (GP) visits. In-patient resources were estimated from the Hospital Episode Statistics. Results were expressed in GBP, 2008. Factors associated with high cost were identifi ed using linear stepwise regression. National extrapolation was performed according to the relative size of the GPRD to the UK general populations. RESULTS: Details of 33,441 patients were extracted, which suggests that about 510,000 patients were treated in the NHS in UK in 2008. The Mean age was 74.2 years, and 47.3% were male. The initial diagnosis was made at 67.8 years. Older patients, longer time since diagnosis, a higher number of previous treatments, a higher number of treatment switches in the previous one year period and use of laser/surgery were associated with a higher annual cost. Spending varied little between regions. Annual drug spending was £91.2 million on inpatient care, £4.4 million on drug prescription renewal (not specifi c to the glaucoma drug). Visits to the GP cost £34.8 million and visits to the eye specialist was >£54.0 million although the latter fi gure is likely to be an under estimate (GPRD underreported eye doctor care). CONCLUSIONS: The 2008 expenditures to care for glaucoma were >£185 million with no regional differences. Three factors were strongly associated with high costs: time since diagnosis, treatment changes, and rescue treatment. This analysis suggests that longer treatment persistence is likely to be associated with cost saving. Published cost-of-illness studies of psoriasis in Sweden are not available. This study estimates the societal cost of psoriasis care in a defi ned Swedish patient population. METHODS: A prevalence-based prospective recruitment of patients visiting two dermatology clinics in Sweden between September and December 2009 was performed. Patients collected resource utilization of health care contacts, treatment, travelling distance and time, and productivity loss (human capital approach) during 1 month (Swedish unit prices, 2009). RESULTS: A total of 164 patients (49% males) were included; average age 52, 76% plaque psoriasis with PASI 5.7, DLQI 7.7 and EQ-5D utility weight 0.71. The mean total cost per patient-month was c994. Main cost drivers were outpatient visits (OP) and light therapy (49%), biological drugs (20%) and productivity loss (22%). When patients were stratifi ed according to treatment strategy, total costs (fraction of patients) for topical treatment only (TT; 34%) was c369, light therapy (LT; 24%) c1274, traditional systemic treatment (TST; 26%) c1085 and biological systemic treatment (BST; 16%) c1709 per patient-month. Main cost drivers in each treatment strategy were: OP (56%) in TT, OP (78%) in LT, productivity loss (40%) in TST and biological drugs (71%) in BST. There was no clear relationship between clinical (PASI) or subjective (DLQI) severity estimations and costs. CONCLUSIONS: In this study the cost-of-illness for a psoriasis patient amounts to almost c1000/month, with great variation depending on treatment strategy. Despite the 1200 difference in drug cost for TST vs. BST, total cost per month differed by c600 because of offsets from improved productivity and reductions in OP and topical treatment. As expected, biologically treated patients had higher costs but lower severity probably due to the treatment effectiveness. The relationship between costs and severity is complex, probably due to the selected study period and differences in effect between strategies.
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COST OF ILLNESS OF PSORIASIS-A 1-MONTH PROSPECTIVE STUDY IN SOUTHERN SWEDEN
PSS7 THE ECONOMIC COST OF TREATING PATIENTS WITH AGE-RELATED MACULAR DEGENERATION IN SPAIN
Darba J 1 , Kaskens L 2 1 Universitat de Barcelona, Barcelona, Spain; 2 BCN Health, Barcelona, Spain OBJECTIVES: Wet macular degeneration associated with age (wet-AMD) is the leading cause of legal blindness in Spain in people over 55. The aim of this study is to determine health care resource utilization and mean costs per patient with wet-AMD in 2009. METHODS: A micro-costing analyses was performed to estimate direct medical costs of patients with wet-AMD. Patient level data was obtained from different public hospitals in Spain and ophthalmologists were surveyed with a semi-structured questionnaire to obtain treatment patterns. Inpatient costs were considered from the perspective of the public health care system. Treatments under study were pegaptanib, verteporfi n, ramibizumab and bavacizumab. Although bevacizumab in Spain is not approved for wet-AMD, it was used off-label in the hospital. Direct medical costs considered were drug costs, administration cost, doctors' visits, nurse time, ophthalmologist time, anaesthetics, ambulant hospital care, external consultation, surgery and treatment of adverse effects. All costs are referred to 2009. RESULTS: Mean cost per patient treated with wet-AMD represented the following cost for the public health care system: c7290 for pegaptanib, c5810c for verteporfi n, c8650 for ramibizumab and c3110 for bevacizumab. We also estimated that in Spain 180,000 people over 50 years have wet-AMD in 2009. CONCLUSIONS: Pharmacological treatments for wet-AMD are photo dynamic therapy with verteporfi n, pegaptanib, verteporfi n and ramibizumab, with the last one having the highest medical costs. The aging of the population and development of new drugs will probably increase the future economic impact of AMD, which remains a major health care burden.
PSS8 PREDICTIVE FACTORS OF GLAUCOMA TREATMENT COST IN GERMANY
Lorenz K 1 , Wolfram C 1 , Claus V 2 , Plesnila-Frank C 2 , Verboven Y 3 , Pfeiffer N 1 1 Universitätsmedizin Mainz, Mainz, Germany; 2 IMS Health, München, Germany; 3 Alcon Research Ltd., Puurs, Belgium OBJECTIVES: To describe total costs and factors predicting cost in Germany for glaucoma disease states: ocular hypertension (OHT), and early (EARLY), moderate (MOD) and advanced (ADV) glaucoma. METHODS: A 5-year retrospective analysis collected health care utilization, clinical parameters, treatment(s) used and reasons for treatment change. Disease states defi ned by the European Glaucoma Society were applied. Costs for health care resources were based upon the German EBM/OPS code for ambulatory visits/procedures, diagnosis-related groups for hospital procedures and the Rote Liste for medication. Factors predicting cost were identifi ed using stepwise backward multiple linear regression, entry criterion a = 0.2. RESULTS: A total of 154 patients (27 OHT, 43 EARLY, 35 MOD, 49 ADV) were enrolled from 15 centers across 5 German regions. Average age was 67 ± 11 and 57% were female. Number of years since diagnosis was 9.0 ± 5.7, 8.7 ± 4.6, 8.7 ± 4.1 and 13.2 ± 8.3 years for OHT, EARLY, MOD and ADV, respectively. Total costs, for patients with OHT, EARLY, MOD or ADV, were c226 ± 117, c423 ± 647, c493 ± 385, and c808 ± 877, respectively. Most costs were due to medication (c121 ± 99, c217 ± 150, c245 ± 161, c340 ± 193) and hospital interventions (c32 ± 101, c115 ± 538, c154 ± 285, c367 ±
